Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825009 | 0.81 | ENPP2 (0.56) | ENPP2SIRT2 | |
| SCHEMBL14289994 | 0.77 | SIRT2 (0.46) | ENPP2SIRT2 | |
| SCHEMBL13514515 | 0.77 | ENPP2 (0.50) | ENPP2SIRT2 | |
| SCHEMBL14496826 | 0.77 | ALDH1A1 (0.49) | ENPP2SIRT2 | |
| SCHEMBL4868116 | 0.76 | ENPP2 (0.50) | ENPP2SIRT2 | |
| SCHEMBL29903179 | 0.75 | ENPP2 (0.44) | ENPP2SIRT2 | |
| SCHEMBL14496825 | 0.74 | ENPP2 (0.47) | ENPP2 | |
| SCHEMBL9088148 | 0.73 | ENPP2 (0.41) | ENPP2SIRT2 | |
| SCHEMBL3065782 | 0.72 | ENPP2 (0.48) | ENPP2SIRT2 | |
| SCHEMBL7786468 | 0.72 | ENPP2 (0.50) | ENPP2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773788-B1 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| CN-1989113-B | Quinazoline derivatives | NOVARTIS AG | 2011-02-16 | — | — | CN | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| CN-1989113-A | Quinazoline derivatives | NOVARTIS AG (CH) | 2007-06-27 | — | — | CN | disclosed |
| EP-1773788-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS-PHARMA GMBH (AT) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010591-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208018-A1 | Quinazoline Derivatives | CYP3A5, CYP3A7, CYP3A4 | ENPP2 3497/4885SIRT2 186/4885SYK 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.